Inhibition of proteasome activity by the dietary flavonoid *Quercetin* associated with growth inhibition in cultured breast cancer cells and xenografts

Debasish Pradhan*, Rakesh Kumar Pradhan, Gitanjali Tripathy, Shaktiprasad Pradhan

Department of Pharmaceutical Sciences, Utkal University, Vanivihar, Bhubaneswar, Odisha, India.

**ABSTRACT**

**Objective:** To study the inhibition of proteasome activity by the dietary flavonoid *Quercetin* associated with growth inhibition in cultured breast cancer cells and xenografts. **Methods:** MCF-7 breast cancer cell cultures and xenografts were treated with *quercetin*, carried out by following measurement of reduced cellular viability/proliferation, proteasome inhibition, and apoptosis induction. Inhibition of the proteasome was decided by levels of the proteasomal chymotrypsin-like activity, by target proteins, and by accumulation of proteasome target proteins in extracts of the treated cells or tumors. Apoptotic cell inhibition was measured by caspase-3/caspase-7 activation, poly (ADP-ribose) polymerase cleavage, and immunohistochemistry for terminal nucleotidyl transferase. **Results:** This result is carried out for the first time by us that *quercetin* inhibits the proteasomal chymotrypsin-like activity and induces apoptosis not only in cultured MCF-7 cell lines but also in MCF-7 xenografts moreover, while *quercetin* has antibreast tumor activity and no toxicity was observed to the tested animals. **Conclusion:** We have shown that *quercetin* is an effective proteasome inhibitor in cultured breast cancer cells and in breast cancer xenografts. Furthermore, *quercetin* induces apoptotic cell death in human breast cancer cells and exhibits anticancer activities in tumors. The results suggest its potential benefits in breast cancer prevention and treatment.

**Key words:** Breast cancer, MCF-7, Proteasome activity, *Quercetin*, Xenografts.

**INTRODUCTION**

Consistent consumption of polyphenols has been related with decreased cancers and with tumour development treatment.\(^1\) The polyphenolic flavone *quercetin* is broadly distributed among fruits and vegetables, and *quercetin* has been indicated to have chemopreventive activities in a number of cancer models including those of lung cancer,\(^2\) skin cancer,\(^3\) cervical cancer,\(^4\) prostate cancer,\(^5\) and leukemia.\(^6\) The mechanism by which *quercetin* imparts its anticancer activities are varied and may possess activity through antiinflammation,\(^7\) free radical scavenging,\(^8\) and proteasome inhibitions.\(^9\) The eukaryotic proteasome is a large multicatalytic, multisubunit protease complex having three distinct activities, which are related with three different $\beta$ subunits, respectively: chymotrypsin-like activity (with the $\beta$5 subunit), trypsin-like activity (with the $\beta$2 subunit), and peptidyl-glutamyl peptide-hydrolyzing-like (caspase-
like) activity (with the β1 subunit).\textsuperscript{10} Chymotrypsin-like activity inhibition and not the trypsin-like activity of the proteasome has been associated with induction of tumour cell apoptosis.\textsuperscript{11} By inspecting a wide range of cell culture models, it has been discovered that proteasome inhibitors quickly induce tumour cell apoptosis, specifically initiate the cell death programme in cancer or oncogen-transferred cells, however not in normal or untransformed cells, and are capable to trigger apoptotic death in human cancer cells that are resistant to different anticancer agents.\textsuperscript{12}

The most depicted proteasome inhibitor, PS-341, is a dipeptide boronic acid analog with the cell-death-inducing activity found in several tumour cell lines.\textsuperscript{13} The mechanism of action of PS-341 has been indicated to be Inhibition of the β5-subunit and the β1-subunit, with the β5-subunit as the dominant cell-death impelling targets.

Since clinically accessible proteasome inhibitors are related with some toxicity,\textsuperscript{14} natural proteasome inhibitors with less or no toxicity are alluring potential anticancer agents. Quercetin potently inhibits the chymotrypsin-like activity of a purified 20s proteasome and 30s proteasome in cultured tumour leukemia cells.\textsuperscript{8} Proteasome inhibition drove to the accumulation of proteasome target proteins (such as Iκb and Bax) and to subsequent induction of apoptosis in human leukemia cancer cells, as measured by initiation of caspases and cleavage of poly(ADP-ribose) polymerase (PARP).\textsuperscript{9} The chemopreventive impacts of quercetin are charized,\textsuperscript{15} and cytotoxic impacts in leukemia cells was observed.\textsuperscript{9} Whether quercetin has potential antitumor cancer activity and whether it could target the breast cancer proteasome, nonetheless, remain unclear. In the current study, we provide proof that the proteasome-inhibitory activity of quercetin stretches out to breast cancer cells and tumours. Proteasome Inhibition, growth concealment, and apoptosis actuation were observed in cultured breast cancer MCF-7 cell lines treated with quercetin. Quercetin was harmless to ordinary cells\textsuperscript{6} and treatment of breast cancer bearing nude mice with quercetin was analyzed—resulting in tumour development inhibition and massive apoptosis incitement, related with proteasome inhibition \textit{in vivo}. No clear toxicity to the tested animals was observed. The information suggest that quercetin acts as a natural proteasome inhibitor under physiological conditions. While prevention of cancer has been the predominant attribute to quercetin, our discoveries are characteristic of extraordinary potential for tumour treatment.

**MATERIALS AND METHODS**

**MATERIALS**

\textit{Quercetin}, bisbenzimide Hoechst number 33258 stain, 3-[4,5-dimethyltetrazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT), dimethylsulfoxide (DMSO), cremophor and other chemicals were purchased from Sigma-Aldrich...
Pradhan, et al.: Anti cancer activity of Quercetin

(Mumbai, India). RPMI 1640, penicillin, and streptomycin were acquired from Invitrogen (Mumbai, India). The fluorogenic peptide substrates Suc-LLVY-AMC (for the proteasomal chymotrypsin-like development) and N-acetyl-DEVD-AMC (for caspase-3/caspase-7 activity) were from Calbiochem (Pune, India). Mouse monoclonal antibody against human PARP was purchased from LAB Chemicals Pvt. Ltd. (Bhubaneswar, India). Mouse monoclonal antibodies against Bax (B-9), ubiquitin (P4d1), goat polyclonal immunizer against actin (C-11), rabbit polyclonal neutralizing operators against Iκbα (C15), and discretionary antibodies were purchased from ICSCCB (Pune, India). The MCF-7 cell lines were obtained from NCCS Pune, India. The balancing operators of p27 for immunohistochemistry was from UDPS, Utkal University.

**Cell culture and cell extract preparation**

MCF-7 cell lines were grown in RPMI 1640 supplemented with 10% fetal bovine serum, 100 u/ml Penicillin, and 100 µg/ml Streptomycin. Cells were grown at 37°C in a humidified incubator with an atmosphere of 5% CO₂. A whole cell extract was prepared. Briefly, MCF-7 breast cancer cells were grown to 60–70% confluency, and were treated with 25 µm, 50 µm, 75 µm, or 100 µm quercetin or DMSO control (at a concentration measure to the volume used for the most highest concentration of quercetin or ≤0.1%) for 24 hours. At the endpoint of the tests, cells were procured, washed twice with PBS and homogenized in a lysis buffer (50 mm Tris (ph 8.0), 5 mm ethylenediamine tetraacetic acid, 150 mM NaCl, 0.5% NP40). After 30 minutes of shaking at 4°C, the mixtures were centrifuged at 12,000×g for 15 minutes and the supernatants were accumulated.

**Proteasomal chymotrypsin-like and caspase-3/caspase-7 activity assays**

Whole cell extracts (10 µg) of cells treated with quercetin or tumour tissue extracts (10 µg) from human breast tumour xenograft were incubated for 2.5 hours at 37°C in 100 µl assay buffer (50 mmol/l Tris–HCl, ph 7.5) with 10 µmol/l fluorogenic substrate Suc-LLVY-AMC (for proteasomal chymotrypsin-like activity) or Ac-DEVD-AMC (for caspase-3/caspase-7 activity). After incubation, production of free hydrolyzed 7-amino-4-methylcoumarin (AMC) groups liberated by substrate hydrolysis was fluorometrically measured using a Victor 3 Multilabel Counter with an excitation channel of 380 nm and an emission channel of 460 nm (Mumbai, India).

**Cell viability/proliferation assay**

The MTT measure, an index of cell viability and cell growth, was used to determine the effects of different compounds on MCF-7 breast cancer cells. Cells were plated in a 96-well plate and were ended upto 70–80% confluence, followed by extension of each compound at the indicated concentration. After 24 hours of incubation at 37°C, the MTT solution was replaced by 100 ml DMSO. When the blue crystals were dissolved, the optical density (OD) was measured in a Wallac Victor3 TM multilabel plate reader (Perkin Elmer, USA) at a wavelength of 560 nm. The formula used to evaluate the result is as follows:

\[
\text{Inhibition of cell proliferation} \% = \left( \frac{\text{OD of the experimental samples}}{\text{OD of the control}} \right) \times 100\%
\]

All assays were done in triplicate in three independent tests, and the mean value for each test was calculated. The results are indicated as the mean ± standard deviation and are expressed as percentage of the control, which was 100%.

**Cellular morphology analysis**

A Zeiss Axiovert 25 microscope (Pune, India) was used for all microscopic imaging with either phase contrast for cellular morphology. Cells collected as a detached fraction, were washed with ice cold PBS and then fixed in ethanol for 1 hr. Thereafter cells were washed with ice cold PBS and were stained with 50 µM Hoechst and kept in the dark at 4°C for 30 minutes and then visualized using fluorescence microscopy. Punctate and bright staining, or granular and bright staining nuclei were considered apoptotic.

**Western blot analysis**

The entire cell extracts or tumour lysates were separated by SDS-PAGE gel and were transferred to a nitrocellulose membrane. Western blot analysis was performed using specific antibodies against ubiquitin, Bax, Iζxβ, PARP or β-actin, followed by visualization utilizing the enhanced chemiluminescence reagent.

**Human breast tumour Xenograft experiments**

Female athymic nude mice, age 5 weeks, were purchased from NCCS (Pune, India) and were housed 12 hour day and night exposure by the IAEC (UDPS, Utkal University). Human breast cancer MCF-7 cell lines (5×10⁶) suspended in 0.1 ml serum free RPMI 1640 were inoculated subcutaneously in both flanks of every mouse (four mice every group).
When the tumours were sizes of ~120 mm³ on average, the mice were grouped randomly (n=4) and were treated by subcutaneously infusion with 25 or 50 mg/kg quercetin daily, or vehicle (10% DMSO, 40% Cremophor/ethanol (3:1) and 50% PBS). The tumour size was measured each other day utilizing calipers, and the tumour volumes were calculated to standard formula: length×width²/2. Mice were sacrificed after 29 days of treatment. Then the tumours were collected and photograph was taken and the tumour tissues were used for multiple assay.

**Terminal nucleotidyl transferase-mediated nick end labeling and immunohistochemistry using tumour tissue samples**

The terminal nucleotidyl transferase-mediated nick end labeling (TUNEL) assay utilizing an in situ apoptosis detection kit, and immunostaining of p27 were performed. The proteasomal chymotrypsin-like activity assay and western blot analysis utilizing animal tumour samples were performed as above utilizing cultured breast cancer cells.

**Statistical analysis**

To evaluate the difference between a treatment and control, the Student test was applied. The level of significance was set at P < 0.05.

**RESULTS**

*Quercetin* could inhibit cell viability/proliferation and could initiate caspase-3/caspase-7 activity of MCF-7 breast cancer cells in a dose dependent manner. In the present study, we first examined the impacts of *quercetin* (Figure 1a) in a dose dependent manner (25, 50, 75, or 100 μm) on the highly metastatic and invasive human breast cancer cell line, MCF-7 cell lines. The results of an MTT assay shows that *quercetin* inhibited cell viability, and potential proliferation,
Figure 2a: Inhibition of proteasomal chymotrypsin (CT)-like activity by quercetin in MCF-7 cell lines. Cells were treated with various concentrations of quercetin for 24 hours, were harvested and were analyzed for the proteasomal chymotrypsin-like activity in cell extracts.
activity in leukemia Jurkat T cells. We hence speculated that quercetin could likewise target the tumour cellular proteasome in MCF-7 cell lines. To determine whether the reduced cell viability/proliferation by quercetin was due to its proteasome-inhibitory activity, MCF-7 cell lines were treated with 25 μm, 50 μm, 75 μm, or 100 μm quercetin for 24 hours. After treatment, proteins were extracted and were used to measure the proteasome Inhibition by the fluorogenic proteasomal chymotrypsin-like activity assay and by western blot analysis. The proteasomal chymotrypsin-like activity was inhibited by 17%, 20%, 29%, and 40% in the cells treated with 25 μm, 50 μm, 75 μm, and 100 μm quercetin, respectively (Figure 2a). Western blot analysis showed an aggregation of ubiquitinated proteins (indicated by the increased intensity of the protein smear compared with the DMSO control) and the proteasome target protein Bax, most prevalently in cells exposed to the highest concentrations (Figure 2b).

Inhibition of the proteasomal chymotrypsin-like activity, yet not trypsin-like activity, has been indicated to be associated with apoptosis incitement in cancer cells. To identify whether the proteasomal Inhibition is associated with apoptosis incitement in cancer cells,

Quercetin inhibits the development of human breast tumour xenografts, associated with proteasome inhibition and apoptosis incitement in vivo. After we demonstrated that quercetin could inhibit proteasomal activity and induce apoptosis in cultured breast cancer cells (Figures 1 and 2), we then determined whether quercetin could apply antitumour activity and whether that activity is related with proteasome inhibition and apoptosis induction. Breast cancer MCF-7 cell lines (5×10⁶) were implanted subcutaneously in 5-week-old female athymic nude mice. When the tumours reach a discernable size (~120 mm³ on average), the mice were treated subcutaneously with either the vehicle control or with 25 or 50 mg/kg quercetin every day. Significant tumour development Inhibition by quercetin was observed after 29 days of treatment, demonstrating that quercetin has antitumour activity (Figure 3a). Control tumours developed to an normal size of 1,077 ± 114 mm³, while 25 mg/kg quercetin-treated tumours developed to 842 ± 71 mm³ and 50 mg/kg quercetin-treated tumours developed to 622 ± 66 mm³. This compares to 22% development Inhibition in the 25 mg/kg quercetin-treated tumours (P<0.05; Figure 3a) and to 43% development Inhibition in the 50 mg/kg quercetin-treated tumours (P<0.01; Figure 3a). We monitored the body weight of mice from every group, and the average body weight on the last day of treatment was 26.8 g, 26.5 g and 26.3 g from the mice treated with the solvent, with 25 mg/kg quercetin, or with 50 mg/kg quercetin, separately. The data of the body weight proposed that there was no toxicity of quercetin.

**DISCUSSION**

Chemotherapy and radiotherapy have a critical part as single modalities for cancer treatment; on the other hand, they generally have limited effectiveness in the treatment of solid human tumours that often get to be drug resistant and are accompanied by severe drug related side effects. In an attempt to enhance conventional treatments, the proteasome has become an increasingly important molecular target.

The antitumour and chemosensitizing properties of the proteasome inhibitor PS-341 are well documented.
Toxicity from bortezomib, however, has started an interest for recognizing nontoxic natural proteasome inhibitors such as the flavonoid quercetin that could potentially serve as nontoxic therapeutic and chemopreventive methodologies. Quercetin and other flavonoids were demonstrated to have proteasome-inhibitory action in human tumour cells, yet had little to no effect on typical, nontransformed cells.

We examined the effectiveness of quercetin in a breast cancer model utilizing human MCF-7 cell lines. After 24 hours, quercetin treatment inhibited breast cancer cell viability/proliferation by half with the highest concentration (Figure 1b). Quercetin is capable to inhibit the chymotrypsin-like activity of a purified 20s proteasome.6 We therefore estimated that the decreased cell viability or possibly reduced proliferation was due in large part to quercetin’s proteasomal inhibitory activity. To test this hypothesis, MCF-7 cell lines were treated for 24 hours with quercetin, were gathered and lysed, and the cell extracts were examined for their chymotrypsin-like activity and by western blot analysis. At the highest concentration, proteasome activity was inhibited by approximately 40% (Figure 2a) and accumulation levels of ubiquitinated proteins, Bax and ubiquitinated Iκbα were observed (Figure 2b). It is likely that an extended treatment in this in vitro model would give even more striking information.

To guarantee that the obvious proteasome inhibition by quercetin treatment would lead to the induction of apoptosis, we analyzed the morphological changes, the event of activated caspase-3/caspase-7 activity and, at last, the production of the sliced PARP fragments. MCF-7 cell lines exposed to quercetin showed changes in cellular morphology that might demonstrate a cellular stress (Figure 1d). A true measure of apoptosis in quercetin-treated cells was observed by caspase-3/caspase-7 activation and sliced PARP most noticeably after treatment with the highest concentration of quercetin (Figures 1c and 2b).

Since the in vitro findings in this epithelial cancer model were so promising, we then inspected the effects of quercetin treatment in a mouse model. Quercetin has been demonstrated to have growth inhibitory effects associated with cell-cycle regulation in nude mice bearing prostate cancer tumours.22 In our current study, treatment with quercetin resulted in prominent inhibition of proteasomal chymotrypsin-like activity (Figure 3b), accumulation of proteasome target proteins (that is Bax), and induction of apoptosis in tumours (Figure 3c and 3d). Associated with the observed proteasome Inhibition and apoptosis actuation, significant tumour development Inhibition (~43%) by quercetin at the highest concentration was observed in this breast tumour model (Figure 3a).

In the present work we have demonstrated that quercetin, at moderately high dosages, exhibits no toxicity in an
animal model while exerting proteasome-inhibitory and development inhibitory effects both in vitro and in vivo. This finding is of specific significance for future studies, which might incorporate the conveyance of quercetin in mix with other natural mixes or as a sensitising agent to conventional cancer therapeutics. In reality, a recent study proposed that quercetin might sensitize leukemia cells, prostate cancer cells, and colon cancer cells by inducing the expression of death receptor 5, which, in combination with exogenous tumour necrosis factor related apoptosis-inducing ligand, acts synergistically to induce apoptosis while having no effect on ordinary cells. The evidence from these studies recommends that quercetin has great potential to be further developed as a cancer therapeutic.

The concentrations of quercetin used to treat cultured breast cancer cells and used as a part of the animal model is most likely higher than those found in the blood of people consuming dietary quercetin. The dose for quercetin in this mouse model, however, seemed to be well tolerated. During the 29-day treatment, there was no severe toxicity observed. More definite microscopic and macroscopic pathologic studies are needed to definitively record the lack of toxicity when quercetin is used at these concentrations.

CONCLUSION

The criticalness of the proteasome in the pathologic state of cancer and the potential for quercetin and other flavonoids as characteristic inhibitors of the proteasome might give a practical modality for the avoidance and treatment of some cancers. The findings reported in the present article demonstrate that quercetin seems to be a guaranteeing, novel anticancer agent, and one of its mechanism of action includes targeting on the tumour cellular proteasome and inducing apoptotic cell death. Utilizing an innocuous natural product or its prodrug as a chemosensitizer might lowers the toxicity and boost the effectiveness of current chemotherapeutics. Future analysis of quercetin in a combinational regimen might illustrate expanded effectiveness of this novel agent in additional cancer models.

ABBREVIATIONS

AMC: 7-amino-4-methylcoumarin;  
DMSO: dimethylsulfoxide;  
MTT: 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide;  
PARP: poly(ADP-ribose) polymerase;  
PBS: phosphate-buffered saline;  
TUNEL: Terminal nucleotidyl transferase-mediated nick end labeling.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of Interest.

ACKNOWLEDGEMENTS

This work is partially supported by research grants from the DST, New-Delhi. The authors thank HOD, UDPS for his kind cooperation and assistance with experimental data acquisition. The authors are also grateful to National Centre for Cell Science (NCCS, PUNE, INDIA) for providing MCF-7 cancer cell lines.

Highlights of Paper

Quercetin inhibits proteasome activity associated with breast cancer cells and xenografts.
Quercetin inhibits the proteasomal chymotrypsin-like activity and induces apoptosis in cultured MCF-7 cell lines and MCF-7 xenografts.
Quercetin has anti breast tumour activity and no toxicity in animals.

Author Profile

Dr. Debasish Pradhan is Sr. Faculty in Pharmacology at University Department of Pharmaceutical Sciences, Utkal University, Bhubaneswar, Odisha. His research interests are in the field of organization designs that maximize innovative patents. Currently he is a member of International Society of Ethno pharmacology; Institutional Animal Ethical Committee, UDPS, Utkal University; ISTE, Orissa branch; O.R/L.M.-70 APTI.

Mr. Rakesh Kumar Pradhan is a Master Degree holder in Pharmacy from University Department of Pharmaceutical Sciences, Utkal University, Bhubaneswar, Odisha.
REFERENCES